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ABSTRACT Application of recombinant human eryth-
ropoietin (rhEpo) improves exercise capacity by stimulat-
ing red blood cell production that, in turn, enhances
oxygen delivery and utilization. Apart from this, when
applied at high doses, rhEpo crosses the blood-brain
barrier, triggering protective neuronal effects. Here we
show a fundamental new role by which the presence of
Epo in the brain augments exercise performance without
altering red blood cell production. Two different animal
models, the transgenic mouse line Tg21, which constitu-
tively overexpresses human Epo exclusively in the brain
without affecting erythropoiesis, and wild-type mice
treated with a single high dose of rhEpo, demonstrate an
unexpected improvement in maximal exercise perfor-
mance independent of changes in total hemoglobin mass,
as well as in whole blood volume and cardiovascular
parameters. This novel finding builds a more complete
understanding regarding the central effects of endoge-
nously produced and exogenously applied Epo on exer-
cise performance.—Schuler, B., Vogel, J., Grenacher, B.,
Jacobs, R. A., Arras, M., Gassmann, M. Acute and chronic
elevation of erythropoietin in the brain improves exercise
performance in mice without inducing erythropoiesis.
FASEB J. 26, 000–000 (2012). www.fasebj.org
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The primary function of the kidney-derived erythropoi-
etic growth factor erythropoietin (Epo) is to promote red
blood cell production by stimulating proliferation, differ-
entiation, and maturation of erythroid progenitors in
bone marrow (1). Accordingly, recombinant human
erythropoietin (rhEpo) is commonly used for the treat-
ment of various forms of anemia, including that due to
kidney failure or following chemotherapy (2). Attendant
to the increase in erythrocyte volume and total hemoglo-
bin mass (tHb) following rhEpo treatment is an increase
in oxygen (O2) carrying capacity that improves maximal
O2 uptake (Vo2max) and overall exercise performance (3,
4) at sea level. Accordingly, the manipulation of tHb via
rhEpo has been embraced as an ergogenic aid in endur-
ance sports.
The identification of extravascular Epo, such as that
found in the brain (5, 6), has culminated in the
identification of a large number of nonerythroid effects
of Epo. Larger doses of systemically administered
rhEpo have been shown to not only cross the blood-
brain barrier but also to trigger neuroprotective and
neurotrophic effects in animal models, as well as in
patients presenting with central nerve damage or neu-
rodegenerative diseases in the brain (7) and even in the
eye (8–10). A few studies in humans, either patients or
volunteers, have investigated the effect of rhEpo as a
treatment for diseases associated with neuronal cell
death, including stroke and depression (11, 12). More-
over, Miskowiak and colleagues (12–14) have recently
shown that Epo activates areas of the brain that are
involved in memory retention and fear processing in
healthy subjects. In correlation with increased brain
activity, humans treated with rhEpo have been claimed
to develop enhanced memory (15) and mood improve-
ment (13) as well as perceived elevated physical condi-
tion and strength scores (16). Notably, those subjects
declared a boost in energy and an increase in overall
self-esteem on receiving rhEpo, a fact that might have
euphoric effects on self-perception. Consequently the
latter may have influence exercise performance by
modulating mechanisms associated with central fatigue
(17). In contrast, a recent study claimed that elevated
cerebral Epo level affects neither exercise performance
nor cognition and voluntary activation in healthy sub-
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jects (18). As the neuroprotective effect of Epo occurs
in a dose- and time-dependent manner (19, 20), how-
ever, the amount of rhEpo applied by Rasmussen et al.
(18) might have been too low and/or not administered
long enough to enhance exercise performance.
We hypothesized that chronic elevated levels of cere-
bral Epo, independent of changes in Epo plasma levels,
hemoglobin (Hb) concentration, or hematocrit (Htc),
enhances exercise performance. To test this notion, we
made use of our transgenic mice, termed Tg21, which
constitutively overexpress human Epo cDNA exclusively
in the brain in an oxygen-independent manner (21).
Moreover, to confirm that rhEpo indeed does cross the
blood-brain barrier and to show a central effect of Epo
on exercise performance, very high doses of rhEpo
were acutely administered in wild-type (WTrhEpo)
mice. Both animal models showed elevated cerebral
Epo levels, whereas tHb and blood volume remained
unaltered. Metabolic and cardiovascular parameters
were measured at rest in addition to an incremental
and constant load exercise test.
MATERIALS AND METHODS
Experimental animals and setup
The transgenic mouse line TgN(PDGFBEPO)322ZbZ (Tg21)
exhibits elevated Epo levels in the brain but not in the
circulation (21). This line was generated by microinjection of
the full-length human Epo cDNA, driven by the human
platelet-derived growth factor (PDGF) B-chain promoter, into
pronuclei of fertilized oocytes derived from B6C3 hybrid mice
(22). Transgenic mice were bred to homozygosity (23). For
experimentation, only homozygous Tg21 and WT male mice
were used. All mice were housed in standard rodent cages
(T3) with fixed temperature (211°C), free access to food
and water, and a 12-h light-dark cycle. Mice were 12 wk of age
at the first exercise test. Compared to the WT controls, we did
not observe elevated spontaneous activity of the Tg21 mice, as
determined by comparing the counts of spontaneous visits of
the animals to the corners of the Intellicage (http://
www.newbehavoiur.com), an automated home cage (data not
shown). The experimental protocols were approved by the
Kantonales Veterinäramt Zürich and were performed in
accordance with the Swiss animal protection laws and institu-
tional guidelines.
A diagram illustrating the experimental timeline is given in
Fig. 1. When mice were 6 wk old, telemetric blood pressure
transmitters were implanted in Tg21 (n12) and WT (n19)
mice. Following sensor implantation, the animals were allowed
to recover fully, using a 2-wk postoperative intensive care regime,
as described previously (24), followed by an additional 2 wk of
normal housing. At 10 wk of age, all animals were habituated to
run on a rodent-specific motorized treadmill 1/wk. About 4-6
h before performing a graded test, WT (WTEpo, n9) mice
were i.v. (tail vein) injected with rhEpo (2000 IU; Eprex;
Janssen-Cilag AG, Baar, Switzerland), whereas Tg21 mice and
WT control animals (n12 and 10, respectively) received an
isovolemic dose of saline (0.9%). To avoid any possible influ-
ence of the circadian rhythm, all measurements were performed
at the same time of day. Necropsy did not reveal any signs of
thromboembolism, as tested in all available organs, as described
earlier (25).
Implantation of telemetric transmitters
Blood pressure sensors were implanted as described previously
(24). In short, inhalation anesthesia was induced and main-
tained with 3.5-4% sevoflurane. After shaving and disinfecting
the neck, the left common carotid artery was localized and
isolated. A catheter extending from the body of the transmitter
was inserted into the artery and pushed forward until the tip just
entered the thoracic aorta. The transmitter body was fixed
under the skin on the mouse’s upper dorsum. Transmitter
implantations were carried out under aseptic conditions. Mice
were allowed to recover for total 4 wk before the experiment was
started. Cardiovascular measurements were performed using a
TA11PA-C10 transmitter (DataSciences International, St. Paul,
MN, USA). Data were reordered by the Dataquest A.R.T 3.0
software (DataSciences International).
Exercise performance
All animals performed a maximal incremental exercise test,
followed by a maximal constant load exercise test on the next
day, using a Columbus Instrument Simplex II metabolic
rodent treadmill fitted with an Oxymax gas analyzer (Colum-
bus Instruments, Columbus, OH, USA). This system measures
Vo2 and carbon dioxide production (V˙co2). Respiratory
exchange ratio (RER) is then calculated using V˙co2/V˙o2.
Prior to each exercise test, the gas analyzer was calibrated with
a high-precision standard gas mixture. A mild electric shock
(0.2 mA, pulse 200 ms, 1 Hz) was used to force mice to run on
the belt until exhaustion.
All exercise tests were performed as described previously
(26). Briefly, 10-l blood samples were taken from the tail
vein for determination of Htc before initiation of the incre-
mental exercise test. Mice were then placed within individual
treadmill lanes and closed off from room air for at least 1 h,
allowing them to acclimatize and the air flux to equilibrate.
The end of this period was identified once basal heart rate
(HR), blood pressure, V˙o2, and V˙co2 reached and main-
tained basal levels for 5 min. Workload for the incremental
exercise test began with 2.5 m/min at 0° inclination for 10
min. Thereafter, the intensity was gradually increased by 2.5
m/min and 2.5° every 3 min until exhaustion. Exhaustion was
defined when mice could no longer keep pace with tread
speed. V˙o2max was confirmed once V˙o2 ceased to increase
despite increasing workload. Reported values for blood pres-
age: 1 2 3 4 6 7 8 9 10 11 125
I R
AAA
0 (weeks)
4-6h +24h +24h
rhEpo
VO2max TTE euthanasia
.Figure 1. Timeline of animal age and experi-mental setup. I, implantation of the telemetric
transmitter; R, recovery with postoperative
care; A, habituation to motorized treadmill
running, rhEpo: injection of rhEpo; V˙o2max,
start of incremental exercise test; TTE, start of
time to exhaustion (constant load) test; eutha-
nasia, animal euthanasia, including blood and
organ harvest.
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sure and HR at exhaustion were based on a 1-min average taken
during the last minute of exercise, or, for V˙o2max, the highest
1-min interval (26). From these values, the O2 pulse and rate
pressure product (RPP) were calculated to assess the stroke
volume and myocardial V˙o2, respectively.
Following 24 h of rest, all mice performed a constant
workload exercise test to exhaustion. The workload was set to
80% of the maximal workload attained during the incremen-
tal exercise test. Prior to this test, animals were allowed to
become familiarized to the treadmill lane for 1 h. Mice
initially warmed up for 10 min at 20%, followed by an
additional 10 min at 40% of the maximal attained power
output of the V˙o2max test. Time to exhaustion at 80%
maximal workload was measured, and exhaustion again was
defined as the inability to continue regular treadmill running
despite repeated electrical stimuli.
Blood analysis
One day after performing the constant workload test, mice
were anesthetized with a subcutaneous injection containing
100 mg/kg ketamine (Ketasol-100; Dr. Graub, Bern, Switzer-
land), 20 mg/kg xylazine (Rompun; Bayer, Leverkusen, Ger-
many), and 3 mg/kg acepromazine (Sedalin; Chassot, Belp,
Bern, Switzerland). Catheters were then introduced into the
left femoral artery and vein. A small sample of blood was
taken for arterial acid-base status, and then Evans blue dye
(10 l) was injected into the femoral vein. After 20 min,
animals were terminally bled, and the blood collected was
used to determine plasma Epo concentration, Htc, and tHb,
as well as plasma and blood volume. The brain was harvested
for analysis of cerebral tissue Epo.
The Htc of heparinized blood was measured in duplicate
using a microcentrifuge (Autokrit II; Pharmap, Geneva, Swit-
zerland), and [Hb] was determined by use of Abbott Cell Dyn
3500 (Abbott Diagnostic Division, Santa Clara, CA, USA). tHb
mass was calculated from the Hb concentration and blood
volume (see below).
Quantification of blood volume has been described previ-
ously (27). Briefly, 10 l Evans blue solution (1% in saline)
was injected into a femoral vein catheter. The plasma con-
centration of Evans blue was measured photometrically.
Plasma volume and Htc values allowed calculation of the
blood volume.
Measurement of Epo in plasma and brain tissue
Epo in plasma and cerebral tissue was measured using a
commercial kit (Epo-Trac 125I RIA kit; DiaSorin, Saluggia,
Italy) as described previously (28).
Statistics
All data were analyzed using StatView 4.57 software (Abacus
Concepts, Berkeley, CA, USA). Results are expressed as
means  sd. Comparisons between experimental groups
were performed using ANOVA followed by post hoc Bonfer-
roni to detect significant differences. Statistical difference was
set at P  0.05.
RESULTS
Elevated Epo levels in the brain of WTrhEpo and
Tg21 mice
Before starting the exercise performance tests, we
compared several parameters of the different mouse
groups. Male WT, WTrhEpo (on acute intravenous
injection of 2000 IU Eprex), and Tg21 mice (that
constitutively express human Epo in brain only)
showed no difference in age, body weight, Htc, basal
mean arterial blood pressure (MAP), HR, V˙o2, or RER
before performing the graded exercise test (Table 1).
We determined Epo levels in blood and brain after
exercise performance according to the timeline shown
in Fig. 1. As expected, the plasma Epo level was elevated
in the WTrhEpo group but not in the WT control or
in the transgenic group (Fig. 2). Also expected was the
elevation of Epo levels in the brain of WTrhEpo and
Tg21 mice (Fig. 2).
Total Hb is not altered in either WTrhEpo or Tg21
mice
It is well established that Epo enhances exercise perfor-
mance by stimulating erythropoiesis, resulting in im-
proved O2 transport capacity due to elevation in tHb
(26). Note, however, that the exercise performance
tests were started 4-6 h after injection of rhEpo into WT
mice (WTrhEpo), thereby minimizing the time pe-
riod in which Epo could stimulate red blood cell
production in this mouse group. On the other hand,
Tg21 mice were never observed to elevate their blood
parameters, as these transgenic mice show elevation of
human Epo exclusively in the brain. Thus, as expected,
neither tHb nor plasma or blood volume was altered in
all mice at the end of the experiment (Fig. 3).
Increased Epo levels in brain improve exercise
performance
To characterize the effect of brain Epo on exercise
performance, mice were subjected to incremental and
constant load exercise tests. Both acutely (WTrhEpo
group) and chronically (Tg21 group) elevated levels of
Epo in the brain markedly improved V˙o2max and time
to exhaustion (Fig. 4) compared to the control group.
The maximal effort of the animals at V˙o2max was
assessed by the RER (29). Despite not reaching signif-
TABLE 1. Basal parameters of WT, WTrhEpo, and Tg21 mice before performing the graded exercise test
Type Weight (g) Age (d) Htc (%) V˙o2 (ml/kg/min) RER MAP (mmHg) HR (min
 1)
WT 25.6  2.3 87.3  6.1 40.6  2.2 50.5  2.5 0.83  0.01 100.7  6.0 500.7  42.2
WTrhEpo 27.1  2.8 85.6  4.3 41.8  1.9 50.8  3.0 0.81  0.01 101.0  9.2 516.7  36.5
Tg21 25.9  1.2 86.9  2.3 40.0  0.6 50.1  2.4 0.82  0.01 103.6  7.3 524.4  46.2
Values represent means  sd.
3CEREBRAL EFFECTS OF EPO ON EXERCISE PERFORMANCE
icance, we interestingly observed a tendency of a higher
RER in WTrhEpo and Tg21 mice (Fig. 4).
No alterations of maximal MAP, HR, stroke volume,
and myocardial V˙O2max occur during exercise
MAP, HR, and stroke volume were quantified at
V˙o2max. MAP and HR did not differ between WT,
WTrhEpo, or Tg21 mice (Fig. 5). As a previous study
has identified a correlation between the stroke volume
and O2 pulse in exercising humans (30), we determined
these parameters, too. Figure 5 also shows the O2 pulse of
WT, WTrhEpo, and Tg21 mice, but there was no
difference in O2 pulse across the mouse groups. Finally, to
analyze the effect of myocardial V˙o2 at V˙o2max, the RPP
was calculated and was not found to differ between WT,
WTrhEpo, and Tg21 mice (Fig. 5).
DISCUSSION
This is the first report demonstrating that an elevated
brain Epo level, observed in both WT mice treated with
acute high doses (2000 IU) of rhEpo (WTrhEpo) and
transgenic mice that chronically overexpress human
Epo solely in the brain (Tg21), enhances exercise
capacity, as defined by an increase in maximal aerobic
capacity (V˙o2max) and time to exhaustion. Notably, the
marked elevation in exercise capacity occurs indepen-
dently of changes in hematologic or cardiovascular
(e.g., MAP, HR, and stroke volume) parameters. Thus,
this striking improvement in exercise performance
suggests a direct, nonerythropoietic impact of Epo in
the brain.
In the past, it was thought that the only function of
Epo is the regulation of the red blood cell production.
Very recently, however, Epo has been found to exert
regulatory effects in different organs, such as liver,
heart, kidney, spleen, lung, bone marrow, reproductive
organs, and brain (10, 31). Of note, high plasma Epo
levels facilitate the penetration of the blood-brain bar-
rier. By doing so, Epo has been shown to exert potent
neuroprotective as well as neurotrophic effects, espe-
cially in the damaged central nervous system (11). In
healthy humans, Epo does affect brain areas related to
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learning and emotional processing (12, 14, 32). Also,
endurance athletes treated with rhEpo feel a significant
increase in motivation (16). This marked emotive im-
provement with Epo administration could positively
affect self-perception and motivation while reducing
physical pain as well as mechanisms of central fatigue
for a given workload.
The aforementioned observations, including ours,
are in disagreement with recent data obtained by one
group (18) reporting that exercise performance re-
mains unaltered after administration of relatively high
Epo doses during 3 consecutive days (3 30,000 IU). As
the amount of rhEpo reaching the brain’s neurons is in
the range of 1% only (10), high doses of rhEpo have to
be administrated at once or within a short period of
time (19, 20). In contrast to the human study, in which
volunteers received 3 400 IU rhEpo/kg body weight,
our WTrhEpo group of mice received a tremendously
high rhEpo dose of 77,000 IU/kg body weight at
once. Therefore, it can be argued that the cerebral
rhEpo level reached in the human study was not
sufficient to induce changes in exercise performance.
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There is an additional possible explanation for the
discrepancy between human and animal exercise data:
Several studies have provided evidence to support the
hypothesis that the central nervous system is a limiting
factor for exercise performance (33–35). Although
there is no doubt that a given exercise performance is
determined by metabolic power (35), voluntary exer-
cise performance depends on the motoneuronal activ-
ity, which, in turn, is determined by the metabolic rate.
Interestingly, the central fatigue hypothesis is sup-
ported by results of animal studies, whereas the exper-
imental evidence in humans is not convincing (34).
Accordingly, one might speculate that Epo’s effect on
central fatigue in relation to exercise limiting factor
may be more pronounced in animals than in humans.
The central fatigue hypothesis suggests that glucose,
dopamine, and serotonine as well as noradrenaline
levels in the brain play a key role in limiting maximal
exercise capacity (36, 37). Interestingly, human brain
areas, such as brain stem, cortex, telencephalon (hip-
pocampus), diencephalon (hypothalamus), and mes-
encephalon, all postulated to be activated during cen-
tral fatigue, were shown to bind Epo and to involve
serotonine and dopamine during exhaustion at maxi-
mal exercise intensities (12). Moreover, compared to
WT animals, Tg21 mice, even at rest, have a higher
local cerebral glucose utilization in areas of the brain
stem (potine gray, lateral lemniscus), mesencephalon
(substantia nigra), telencephalon (hippocampus, pyri-
form cortex), and diencephalon (medial geniculate
body) (38). Thus, the improvement in exercise capacity
in WTrhEpo and Tg21 animals may be explained, at
least partially, by reduced central fatigue.
V˙o2max is a well-established parameter to measure
aerobic power of subjects. However, the definition of
the plateau at V˙o2max is highly contentious (39–41). In
humans, as few as 17% (but up to 95%) of individuals
may reach the Vo2max plateau (41, 42), and in animals
this number may even be lower. To identify the plateau,
additional criteria, such as RER  1.5, are typically
included (40). Therefore, at first glance, our mice may
not reach “true” V˙o2max plateau, although they were
completely working to full capacity at the end of the
incremental exercise test. It has to be mentioned,
however, that the measured parameters were in the
range of other studies using similar methodology and
conditions (43–45). Moreover, one must recognize the
technical limitations in measuring V˙o2max in small
animals. Due to the volume ratio between the animal’s
tidal volume and the metabolic chamber, the metabolic
measurements cannot reflect the immediate condition.
This is particularly important to note, as it is known that
the V˙co2 increases to a greater extent compared to the
V˙o2 by the end of the incremental exercise test (46).
Indeed, we found a tendency of increased RER at
V˙o2max in WTrhEpo and Tg21 mice that might indi-
cate that these animals forced themselves to a higher
metabolic rate at maximal exercise.
While the role of Epo on erythroid precursor cells is
well established, the activity of Epo on nonerythroid
tissue is poorly understood. Regarding central effects of
Epo on metabolism and movement, Teng et al. (47)
showed that the absence of the Epo receptor in brain
and other organs, with exception of the hematopoietic
tissue, led to decreased locomotor activity and energy
expenditure. Moreover, the researchers provide evi-
dence that Epo directly regulates expression of pro-
opiomelanocortin (POMC) by binding the Epo recep-
tor present on POMC neurons. Taken together, we
postulate that the increase in cerebral Epo concentra-
tion facilitates its effects on exercise capacity by a
complex response including elevated POMC expres-
sion, by means of enhanced ventilation during exercise-
induced hypoxia (48, 49) and by minimizing central
fatigue.
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